Hepatitis B virus treatment in hepatocellular carcinoma patients prolongs survival and reduces the risk of cancer recurrence

Pazgan−Simon, Monika; Simon, Krzysztof; Jarowicz, Ewa; Rotter, Katarzyna; Szymanek-Pasternak, Anna; Zuwała−Jagiełło, Jolanta

doi:10.5114/ceh.2018.78127

Cited by 28 publications

(25 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A total of 54% of all HCC cases are associated with HBV, making it the most common cause of cancer worldwide[18]. In addition to directly overlapping nodes as the most direct bridge between HBV and HCC, we also analyzed other possible links between inflammation and cancer.…”

Section: Resultsmentioning

confidence: 99%

Identification of hepatitis B virus and liver cancer bridge molecules based on functional module network

Huang

Feng

et al. 2019

WJG

View full text Add to dashboard Cite

BACKGROUNDThe potential role of chronic inflammation in the development of cancer has been widely recognized. However, there has been little research fully and thoroughly exploring the molecular link between hepatitis B virus (HBV) and hepatocellular carcinoma (HCC).AIMTo elucidate the molecular links between HBV and HCC through analyzing the molecular processes of HBV-HCC using a multidimensional approach.METHODSFirst, maladjusted genes shared between HBV and HCC were identified by disease-related differentially expressed genes. Second, the protein-protein interaction network based on dysfunctional genes identified a series of dysfunctional modules and significant crosstalk between modules based on the hypergeometric test. In addition, key regulators were detected by pivot analysis. Finally, targeted drugs that have regulatory effects on diseases were predicted by modular methods and drug target information.RESULTSThe study found that 67 genes continued to increase in the HBV-HCC process. Moreover, 366 overlapping genes in the module network participated in multiple functional blocks. It could be presumed that these genes and their interactions play an important role in the relationship between inflammation and cancer. Correspondingly, significant crosstalk constructed a module level bridge for HBV-HCC molecular processes. On the other hand, a series of non-coding RNAs and transcription factors that have potential pivot regulatory effects on HBV and HCC were identified. Among them, some of the regulators also had persistent disorders in the process of HBV-HCC including microRNA-192, microRNA-215, and microRNA-874, and early growth response 2, FOS, and Kruppel-like factor 4. Therefore, the study concluded that these pivots are the key bridge molecules outside the module. Last but not least, a variety of drugs that may have some potential pharmacological or toxic side effects on HBV-induced HCC were predicted, but their mechanisms still need to be further explored.CONCLUSIONThe results suggest that the persistent inflammatory environment of HBV can be utilized as an important risk factor to induce the occurrence of HCC, which is supported by molecular evidence.

show abstract

Section: Resultsmentioning

confidence: 99%

Identification of hepatitis B virus and liver cancer bridge molecules based on functional module network

Huang

Feng

et al. 2019

WJG

View full text Add to dashboard Cite

show abstract

“…1,2 Majority of chronic cases is caused by vertical transmission. 7,8 According to WHO 2015, 9 after the guidelines for hepatitis B vaccine and immunoglobulin administration was launched, the prevalence of HBsAg-positive cases reduced to only 1.3% worldwide.…”

Section: Women With Chronic Hepatitis B Virus (Hbv) Infection Definementioning

confidence: 99%

“…Chronic hepatitis B infection is accepted as the major cause of liver cirrhosis and hepatocellular carcinoma, and it is the most common medical disorder in pregnant women, especially in low‐income countries . Majority of chronic cases is caused by vertical transmission . According to WHO 2015, after the guidelines for hepatitis B vaccine and immunoglobulin administration was launched, the prevalence of HBsAg‐positive cases reduced to only 1.3% worldwide.…”

Section: Introductionmentioning

confidence: 99%

Placental infection of hepatitis B virus among Thai pregnant women: Clinical risk factors and its association with fetal infection

et al. 2019

View full text Add to dashboard Cite

Objectives To identify the risk factors of placental and fetal infections among HBsAg‐positive women. Methods A prospective cohort study involving HBsAg‐positive pregnant women was conducted. Maternal risk factors, including serum HBeAg status, anti‐HBcIgM, and HBV‐DNA levels, were determined. Placental infection was identified by PCR and confirmed by DNA sequencing. Fetal infection was defined as a positive umbilical cord blood HBV‐DNA at birth. Results A total of 96 HBsAg‐positive women were enrolled in the study. The prevalence of placental infection was high (44 of 96; 45.8%) among HBsAg‐positive women. The major risk factors for placental infection were high maternal viral load and the presence of HBeAg. Fetal infection was detected in one quarter of HBsAg‐positive women (25 of 95; 25.3%). The risk of fetal infection was strongly associated with placental infection (78.3%), high maternal viral load, and the presence of HBeAg. There was no significant difference in perinatal outcomes between the groups with and without placental infection. Data on rates of chronic HBV infection in infants after fetal infection were not available. Conclusion A significant association between maternal measures of viral replication and placental and fetal infection was demonstrated. These findings suggest that transplacental infection prior to birth may be a mechanism contributing to the higher rates of newborn prophylaxis failure in women with a high viral load.

show abstract

“…Treatment of hepatitis B in patients with known HCC is much less controversial. It is generally considered safe and is recommended to administer with concurrent treatment for HCC [62,63].…”

Section: Anti-viral Therapymentioning

confidence: 99%

Medical oncology management of advanced hepatocellular carcinoma 2019: a reality check

Lee

2019

Front. Med.

View full text Add to dashboard Cite

In terms of global cancer-related deaths, hepatocellular carcinoma (HCC) has the fourth highest mortality rate. Up until 2017, treatment of advanced HCC was largely limited to sorafenib, an oral tyrosine kinase inhibitor, with little to no success in the development of alternative treatment options. However, in the past two years, there has been an unprecedented increase in both the number and type of treatment options available for HCC. As of 2019, the US FDA has approved four oral tyrosine kinase inhibitors, two immune checkpoint inhibitors, and one anti-angiogenesis antibody for the treatment of HCC. Even with this new variety, systemic treatment of advanced HCC remains largely unsatisfactory, and the median survival rate stands at approximately one year. The expected breakthrough of using immune checkpoint inhibitors in advanced HCC did not materialize in 2019. The use of immune checkpoint inhibitors in conjunction with oral tyrosine kinase inhibitors or antiangiogenesis medications is the current clinical research trend, the results of which are eagerly anticipated. Despite limited progress in survival, HCC research is currently experiencing a period of growth and innovation, and there is hope for significant advances in the treatment of advanced HCC as the field continues to develop.

show abstract

Hepatitis B virus treatment in hepatocellular carcinoma patients prolongs survival and reduces the risk of cancer recurrence

Cited by 28 publications

References 28 publications

Identification of hepatitis B virus and liver cancer bridge molecules based on functional module network

Identification of hepatitis B virus and liver cancer bridge molecules based on functional module network

Placental infection of hepatitis B virus among Thai pregnant women: Clinical risk factors and its association with fetal infection

Medical oncology management of advanced hepatocellular carcinoma 2019: a reality check

Contact Info

Product

Resources

About